Zealand Pharma's Petrelintide Shows Promising Results in Early Weight Loss Trial

The drug demonstrated significant weight reduction and favorable tolerability, positioning it as a potential alternative to current market leaders.

Petrelintide achieved an average weight loss of 8.6% over 16 weeks in a Phase 1b trial.
The trial involved 48 participants, with the drug showing a better safety profile compared to existing treatments.
Zealand Pharma plans to initiate a Phase 2b clinical trial later in 2024.
The global weight-loss drug market is expected to reach $150 billion by the early 2030s.
Zealand Pharma's stock surged following the announcement of the trial results.